DBP B Stock Overview
A pharmaceutical company, engages in the development and commercialization of approaches for the treatment of oncological, infectious, autoimmune, and other life-threatening diseases.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 4/6 |
Dividends | 0/6 |
Double Bond Pharmaceutical International AB (publ) Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | SEK 0.43 |
52 Week High | SEK 2.00 |
52 Week Low | SEK 0.25 |
Beta | 0.58 |
11 Month Change | 0.95% |
3 Month Change | -26.30% |
1 Year Change | 37.42% |
33 Year Change | -75.63% |
5 Year Change | -92.30% |
Change since IPO | -90.53% |
Recent News & Updates
Recent updates
Shareholder Returns
DBP B | SE Pharmaceuticals | SE Market | |
---|---|---|---|
7D | -4.3% | -2.4% | -4.3% |
1Y | 37.4% | 74.8% | 12.6% |
Return vs Industry: DBP B underperformed the Swedish Pharmaceuticals industry which returned 73% over the past year.
Return vs Market: DBP B exceeded the Swedish Market which returned 12.5% over the past year.
Price Volatility
DBP B volatility | |
---|---|
DBP B Average Weekly Movement | 13.9% |
Pharmaceuticals Industry Average Movement | 10.8% |
Market Average Movement | 5.8% |
10% most volatile stocks in SE Market | 12.2% |
10% least volatile stocks in SE Market | 3.4% |
Stable Share Price: DBP B's share price has been volatile over the past 3 months.
Volatility Over Time: DBP B's weekly volatility has decreased from 20% to 14% over the past year, but is still higher than 75% of Swedish stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2014 | 10 | Igor Lokot | www.doublebp.com |
Double Bond Pharmaceutical International AB (publ), a pharmaceutical company, engages in the development and commercialization of approaches for the treatment of oncological, infectious, autoimmune, and other life-threatening diseases. It offers Temodex, a therapy to treat malignant brain tumors; and SA033, a therapy to treat cancers in liver. The company is also developing Belopenem for the treatment of bacterial pneumonia.
Double Bond Pharmaceutical International AB (publ) Fundamentals Summary
DBP B fundamental statistics | |
---|---|
Market cap | SEK 45.63m |
Earnings (TTM) | -SEK 16.07m |
Revenue (TTM) | SEK 1.49m |
30.6x
P/S Ratio-2.8x
P/E RatioIs DBP B overvalued?
See Fair Value and valuation analysisEarnings & Revenue
DBP B income statement (TTM) | |
---|---|
Revenue | SEK 1.49m |
Cost of Revenue | SEK 3.14m |
Gross Profit | -SEK 1.65m |
Other Expenses | SEK 14.42m |
Earnings | -SEK 16.07m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Aug 26, 2024
Earnings per share (EPS) | -0.15 |
Gross Margin | -110.80% |
Net Profit Margin | -1,078.01% |
Debt/Equity Ratio | 0% |
How did DBP B perform over the long term?
See historical performance and comparison